Differences in sex- and Age-Associated Mortality in Patients with anti-MDA5 Positive Dermatomyositis.

Patients with MDA5+ DM, who received contemporary treatment, had unfavorable outcomes. The 6-month mortality risk increased with age, particularly in male patients aged >54 years.